|| Print ||
|Saturday, December 01, 2007|
It’s a tricky thing to talk up a mouse without getting cheesy. But this little guy, by all appearances a normal rodent, has a human liver inside of it, making it a real-life mighty mouse worth at least five grand. Markus Grompe of the Oregon Stem Cell Center at Oregon Health & Science University is breeding more of this star in hopes of revolutionizing the way drugs are tested. The mouse’s liver is infected with disease and then healthy human liver cells are transplanted into it; these human cells thrive until the liver is only 10% mouse. The new liver allows the mice to metabolize and excrete medications like a human. Pharmaceutical companies testing medication toxicity and searching for disease cures are interested because testing on this mouse is like testing on real human liver cells, which are hard to come by. Previous technology only allowed for an inconsequential number of human cells in mice, and a more recent Japanese version can’t control the liver disease or stop healthy mouse liver cells from regenerating. Those mice have shorter life spans and are difficult to breed, which makes Grompe optimistic that he’s developed a big seller. With the Japanese mice selling for $5,000 each, Grompe could be holding a small, furry fortune in his hands. AMBER NOBE
Friday, July 18, 2014
BY JASON NORRIS | OB GUEST CONTRIBUTOR
Back in May, we shared a common Wall Street quote about investing, “Sell in May and go away.” Fast forward to July and the most common question we have been getting from clients is, “When is the market pullback going to occur?”
Friday, June 27, 2014
BY JASON NORRIS | OB BLOGGER
Over the last several months we have seen a wave of cross-border acquisitions, primarily U.S.-based companies looking to purchase non-U.S.-based companies. There are a few reasons for this, but the main culprit is the U.S. corporate tax system. The United States has one of the highest corporate tax rates in the world.
Thursday, July 31, 2014
BY MARY SPILDE | OB GUEST CONTRIBUTOR
Faced with the aftermath of the “great recession,” increasing concern about the environment and dwindling family wage jobs, we have some very important choices to make about our future.
Monday, June 30, 2014
Oregon Business magazine won two silver awards for excellence in writing in the National American Society of Business Publication Editors Western region competition.
Monday, July 14, 2014
BY TERRY "STARBUCKER" ST. MARIE
I really didn’t know that much about angel investing, but I did know a lot about the entrepreneurial spirit.
Thursday, June 26, 2014
BY ERIC FRUTS | OB BLOGGER
Last year, the housing market in Oregon—and the U.S. as a whole—was blasting off. The Case-Shiller index of home prices ended the year 13% higher than at the beginning of the year. But, was last year a blip, or a trend?
Thursday, July 10, 2014
BY TOM COX | OB BLOGGER
Tom Cox interviews Dr. Mark Goulston, author of Just Listen, Discover the Secret to Getting Through to Absolutely Anyone.
|The Private 150: Bigger But Leaner|
|The Perfect Food|
|Powerlist: Staffing Firms|
|Taxis Uber Alles?|
|Gold futures drop to six-week low|
|The 'Pill' linked to breast cancer risk|
|Adidas reveals profit warning|
|Target appoints new CEO|
|U.S. economy grew by 4% in Q2|
|Twitter Q2 revenue surges|
|Pfizer results beat estimates|
Vigilant enters a New Year with a new president.
How George Fox has become one of Oregon's largest private universities.
Forest Grove sees growth in the burgeoning food and beverage scene.
Lane Powell Shareholder Susan K. Eggum has been elected as vice chair of programs and projects for the International Association of Defense Counsel’s (IADC’s) Employment Law Committee.
Geffen Mesher is saddened to announce the passing of long-time shareholder, Tom “Mike” Anderson, who died on July 10, 2014, from liver disease diagnosed after recent heart surgery. He was 55 years old.
Fifteen Lane Powell attorneys have been named 2014 “Oregon Super Lawyers,” and another five attorneys have been named as “Oregon Rising Stars” by Super Lawyers magazine.